drugset / Trial / NCT01293487

Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.

NCT01293487 ↗

Phase 1 Completed 68 enrolled Pfizer
NaSequentialQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and tolerability of RN564 in women with osteopenia and healthy men.

Timeline

Start
2011-04-01
Primary completion
2012-05-24
Completion
2012-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject RN564 Unknown — Intravenous